Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Issued Notice of Allowance on Dicer-Substrate Technology

Premium

Dicerna Pharmaceuticals said this week that the US Patent and Trademark Office has issued the company a notice of allowance for a patent application covering its core Dicer-substrate technology.

Dicerna did not provide specific details about the intellectual property, but said that the new allowance “applies to 148 claims and provides exclusivity around both in vivo therapeutic and in vitro uses of Dicer-substrates for reducing mammalian target gene expression, regardless of their specific sequence.”

Developed by researchers at the City of Hope and Integrated DNA Technologies, Dicer-substrates are essentially synthetic RNA duplexes around 27 nucleotides long. In animal studies, they have been shown to be more potent than standard 21-mer siRNAs while avoiding immune stimulation.

Dicerna was founded in 2007 to develop the technology for therapeutic applications (GSN 11/8/2007).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more